References
- BlüherMSchweizerABaderGFoleyJEChanges in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetesVasc Health Risk Manag20141066166425429228
- DollSPaccaudFBovetPBurnierMWietlisbachVBody mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countriesInt J Obes Relat Metab Disord2002261485711791146
- FlockMRGreenMHKris-EthertonPMEffects of adiposity on plasma lipid response to reductions in dietary saturated fatty acids and cholesterolAdv Nutr20112326127422332058
- DattiloAMKris-EthertonPMEffects of weight reduction on blood lipids and lipoproteins: a meta-analysisAm J Clin Nutr19925623203281386186
- WilcoxGInsulin and insulin resistanceClin Biochem Rev2005262193916278749
- NeterJEStamBEKokFJGrobbeeDEGeleijnseJMInfluence of weight reduction on blood pressure a meta-analysis of randomized controlled trialsHypertension200342587888412975389
- DejagerSSchweizerAFoleyJEEvidence to support the use of vilda-gliptin monotherapy in the treatment of type 2 diabetes mellitusVasc Health Risk Manag2012833934822661900
- GreenJBBethelMAArmstrongPWEffect of sitagliptin on cardiovascular outcomes in type 2 diabetesN Engl J Med2015373323224226052984
- Galvus® Summary of Product Characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000771/WC500020327.pdfAccessed July 13, 2016